3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
10
Phase 1/2
3
Phase 3
2
Phase 1
2
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
11
Lymphoma, Mantle-Cell
4
Lymphoma, Non-Hodgkin
3
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell
2
Lymphoma
2
Neoplasms
1
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Leukemia, B-Cell
1
Leukemia
1
Hematologic Diseases
1
Interventions
Rituximab
66
Cyclophosphamide
46
Vincristine
40
Doxorubicin
40
Prednisone
35
Etoposide
19
Radiotherapy
14
Gemcitabine
13
Peripheral Blood Stem Cell Transplantation
12
Filgrastim
12
Cytarabine
12
Lenalidomide
11
Carmustine
10
VAP-cyclo protocol
9
Prednisolone
9
Oxaliplatin
9
Melphalan
9
Methotrexate
7
Ifosfamide
7
Mitoxantrone
6
Bleomycin
6
polatuzumab vedotin
5
R-CHOP protocol
4
Methylprednisolone
4
Injections
4
Granulocyte Colony-Stimulating Factor
4
Cyclosporine
4
Cisplatin
4
Carboplatin
4
pegfilgrastim
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, Large B-Cell, Diffuse
×
acalabrutinib
×
Clear all
NCT04529772
2026-03-31
ESCALADE
Acerta Pharma BV
Phase 3
Active not recruiting
611 enrolled
NCT05820841
2023-08-31
ARCHED
Universität des Saarlandes
Phase 3
Recruiting
330 enrolled